3 tracked public figures made calls on ABBV. We grade SELL/REDUCE calls as Correct/Incorrect/Pending, and compare BUY/ADD returns against the S&P 500 over matched windows.
On average, public BUY calls on AbbVie trailed the S&P 500 by +5.2%.
| Who | Signal | Date | Return / Grade | Buy vs S&P | Source |
|---|---|---|---|---|---|
| Scott Wapner | BUY | Feb 27, 2026 | -11.6% | -5.5% | source ↗ |
| Lori Calvasina | BUY | Feb 25, 2026 | -9.6% | -6.4% | source ↗ |
| Scott Minerd | BUY | Mar 12, 2026 | -9.0% | -2.6% | source ↗ |
Lori Calvasina currently ranks #1 on ABBV with -9.6% average buy return vs -6.4% for the S&P 500 (-3.2% alpha) across 1 scored buy calls.
No. Across 3 scored BUY/ADD calls, average return is -10.1% vs -4.8% for the S&P 500 (-5.2% alpha).
SELL/REDUCE calls are shown as Correct, Incorrect, or Pending. Only BUY/ADD calls are compared directly against the S&P 500 in the ticker-level return stats.